Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma
© Tate et al; licensee BioMed Central Ltd. 2008
Received: 29 July 2008
Accepted: 25 September 2008
Published: 25 September 2008
L-arginine is the common substrate for the two isoforms of arginase. Arginase I, highly expressed in the liver and arginase II mainly expressed in the kidney. Arginase I-producing myeloid derived suppressor cells have been shown to inhibit T-cell function by the depletion of L-arginine. On the other hand, arginase II has been detected in patients with cancer and is thought to metabolize L-arginine to L-ornithine needed to sustain rapid tumor growth; however its role in L-arginine depletion is unclear. Thus, in tumor biology, L-arginine metabolism may play a dual role in tumor growth and in the induction of T cell dysfunction. Therefore, we studied in murine renal cell carcinoma (RCC) cell lines, the effect of arginase II on tumor cell proliferation and L-arginine depletion. The effect of arginase inhibitors on cell proliferation was also tested.
Three murine renal cell carcinoma (mRCC) cell lines were tested for the presence of arginase. nor-NOHA, an arginase inhibitor was used to substantiate the effect of arginase on cell growth and L-arginine depletion. Amino acid levels were tested by HPLC.
Our results show that mRCC cell lines express only arginase II and were able to deplete L-arginine from the medium. Cell growth was independent of the amount of arginase activity expressed by the cells. nor-NOHA significantly (P = 0.01) reduced arginase II activity and suppressed cell growth in cells exhibiting high arginase activity.
The depletion of L-arginine by mRCC induced the decrease expression of CD3ζ a key element for T-cell function.
The results of this study show for the first time that arginase II produced by RCC cell lines depletes L-arginine resulting in decreased expression of CD3ζ. These results indicate that RCC cell lines expressing arginase II can modulate the L-arginine metabolic pathway to regulate both cell growth and T-cell function. Blocking arginase may lead to a decrease in RCC cell growth and aid in restoring immune function by increasing L-arginine availability for T-cell use. Understanding the interplay between arginase II and its interaction with the immune system may provide future therapeutic benefits to treat patients with RCC.
L-arginine is a basic amino acid that plays a central role in multiple systems including the immune system [1–3]. Two independent enzymatic pathways, arginase and inducible nitric oxide synthase (iNOS), regulate L-arginine availability. L-arginine is metabolized to L-ornithine and urea by arginase, which is important in the urea cycle and in the biochemical pathways essential for cell proliferation [4, 5]. Arginase has two isoforms: arginase I, a cytosolic enzyme found predominantly in hepatocytes, erythrocytes, and granulocytes [6–8] and arginase II, found in the mitochondria of many different tissues, including kidney, brain, and prostate [6, 9, 10]. Arginase I, is primarily involved in the detoxification of ammonia and urea synthesis, whereas arginase II is involved in the synthesis of L-ornithine, L-proline, and L-glutamate .
Several studies have shown that decreased plasma L-arginine levels and nitric oxide (NO) metabolites induced by trauma are associated with an increase in arginase I expression in mononuclear immune cells [12, 13], suggesting that L-arginine may have an effect on metabolic processing in the immune system. In patients with renal cell carcinoma (RCC), we have demonstrated that arginase I-producing myeloid suppressor cells depletes plasma L-arginine levels that decreases the expression of T-cell CD3ζ chain . Arginase II on the other hand, is constitutively expressed in normal kidney  and its activity shown to be increased in breast, colon, and prostate cancer [16–18]. This activity may sustain the high demand of polyamines necessary for tumor growth. Even though, the depletion of L-arginine has been exclusively attributed to arginase I [19–21], the potential role of arginase II in L-arginine depletion has not been taken into detailed consideration. Likewise, the role of arginase II in tumor growth and in the induction of T-cell dysfunction has not been determined.
In this study we demonstrate for the first time that only arginase II is produced by murine renal cell carcinoma (mRCC) cell lines and that high enzyme levels, specifically depletes extra cellular L-arginine. This amino acid deprivation induces the downregulation of CD3ζ expression in co-cultured Jurkat T-cells. Arginase inhibitors significantly suppressed cell growth in cell lines presenting high arginase II activity.
Tissue culture medium
Complete tissue culture medium consisted of RPMI-1640 containing 1,140 μM L-arginine and supplemented with 10% fetal calf serum (Hyclone, Logan, UT), 25 mM HEPES, 4 mM L-glutamine, and 100 units/mL penicillin/streptomycin, 1 mM non-essential amino acids, and 1 mM sodium pyruvate. All other reagents were purchased from Lonza Walkersville Inc., Walkersville, MD.
For this study we used mRCC cell lines SIRCC-1.2 (CL-2) and SIRCC 1.19 (CL-19), both of which are sub-clones derived from a streptozotocin-induced kidney tumor  and Renca. All of the cell lines were kindly provided by Dr. Robert H. Wiltrout (NCI). Cells were cultured at 37°C in complete media and subcultured every 3 days. Experiments were prepared by plating 300,000 cells in six-well plates and allowed to attach for 24 hours. Media was changed (Time 0) to perform all of the experiments. The cells were harvested at 24, 48, and 72 hours using 0.5% Trypsin/EDTA (Sigma, St. Louis, MO) and lysed with a Triton-based buffer  to obtain cytoplasmic extracts to test immediately for arginase activity. Protein concentration was determined by the BCA (bicinchoninic acid) protein assay kit (Pierce Biotechnology Inc., Rockford, IL). Lysates were stored at -70°C until used for Western blots.
Freshly prepared cytoplasmic extracts from cultured mRCC cells were tested for arginase activity by the conversion of L-arginine to L-ornithine (nanomoles/106cells/hr), as described elsewhere .
Twenty-five micrograms of cytoplasmic extract were electrophoresed in 14% Tris-glycine gels (Invitrogen, Carlsbad, CA) and transferred to polyvinylidiene difluoride (PVDF) membranes (Invitrogen). Immunoblotting were performed with antibodies for arginase I or arginase II (1:200, Santa Cruz Biotech, Santa Cruz, CA). Detection was achieved by horseradish peroxidase-conjugated antibodies (1:3000, Santa Cruz) and an enhanced chemiluminescent kit (ECL, GE Healthcare, Piscataway, NJ). Arginase protein levels were visualized on X-OMAT AR films (Kodak, Rochester, NY).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA from 1 × 106 cells were extracted using TRIzol (Invitrogen), treated with DNase I (Invitrogen), and reverse transcribed using Superscript II (Invitrogen). PCR amplification was done using primers for mouse arginase I, arginase II, and β-actin as follow: Arginase I forward 5'-CAG AAG AAT GGA AGA GTC AG-3', reverse 5'-CAG ATA TGC AGG GAG TCA CC-3', Arginase II forward 5'-TGA TTG GCA AAA GGC AGA GG-3', reverse 5'-CTA GGA GTA GGA AGG TGG TC-3', and β-actin forward 5'-CCA GAG CAA GAG AGG TAT CC-3', reverse 5'-CTG TGG TGG TGA AGC TGT AG-3'. The expected sizes of amplified fragments were arginase I, 250 bp; arginase II, 310 bp; and β-actin, 436 bp. PCR products were visualized in ethidium bromide agarose gels.
Amino acid detection
High performance liquid chromatography (HPLC) was conducted on deproteinized supernatants labeled with O-phtaldialdehyde (OPA). Analytes were eluted with 100 mM sodium acetate buffer, pH 5.0, with a linear gradient consisting of methanol (80%) and acetonitrile (80%). The analytes in the sample were calculated on the basis of standard curves of known amounts.
Cells (1 × 104/well/1 mL) were plated in 24-well plates and allowed to adhere for 24 hours. The cells were treated with different concentrations of Nω-Hydroxy-nor-L-arginine (nor-NOHA), 0.5 mM, 1 mM, and 2 mM to determine the optimal conditions to suppress cell growth, or cultured without the inhibitor to be used as controls. The cultures were pulsed once with [3H]-thymidine (1.0 μCi, Perkin Elmer Life Sciences, Boston, MA) and tested for [3H] incorporation at 24, 48, and 72 hours using a TOPCOUNT Microplate Scintillation Counter (Packard, Meridien, CT). Cell viability was checked by trypan blue exclusion at each time point. Each condition was tested in triplicate.
Expression of CD3ζ by co-cultured Jurkat T-cells
To determine the effect of L-arginine deprivation on the expression of CD3ζ, mRCC cell lines (600,000 cells/well) were cultured in six-well plates with 5 mL of complete media for 24 hours. 5 × 105 Jurkat T-cells (ATCC, Manassas, VA) were then added to the upper chamber of a trans-well system (Falcon-BD, San Jose, CA) and co-cultured for 24, 48, and 72 hours. CD3ζ expression was determined by flow cytometry as described elsewhere . Jurkat cells cultured in complete media were used as controls. L-arginine levels were determined in the supernatants by HPLC.
Statistical analysis was calculated by Student's t-test using the Graph Pad Prism 3.0 statistical program (GraphPad Software Inc., San Diego, CA). P < 0.05 was taken to indicate statistical significance.
Arginase expression in mRCC cell lines
Arginase II produced by the CL-19 cell line depletes extra cellular L-arginine
Role of arginase II and effect of nor-NOHA on mRCC cell proliferation
We assessed whether arginase II could play a role in the proliferation of the three different mRCC cell lines. The cell lines were cultured for 24 hours and the media replaced with 0.5, 1 and 2 mM of nor-NOHA, pulsed once with [3H]-thymidine and tested for [3H] incorporation after 24, 48, and 72 hours in culture. At 72 hours in culture a concentration of 2 mM nor-NOHA was able to significantly suppress cell growth in the high arginase producer CL-19 cell line. No significant effect on cell growth suppression was observed with the lower concentrations of nor-NOHA (data not shown). Therefore, we used 2 mM nor-NOHA for the rest of the experiments.
We then tested the effect of the arginase inhibition by nor-NOHA (2 mM) on cell proliferation at 24, 48, and 72 hours. Growth of CL-19, which had the highest level of arginase II activity, was significantly inhibited (P = 0.017, Figure 3B). In contrast, nor-NOHA had no significant effects on the growth rates of the low arginase producer cell lines CL-2 (P = 0.14) and Renca (P = 0.07). Cell viability of the cells was > 95% at the different points and conditions of the experiments.
nor-NOHA blocks arginase activity and L-arginine consumption in CL-19 cell line
L-arginine depletion by arginase II induces CD3ζ downregulation in Jurkat T-cells
Our major objective was to assess whether arginase II was able to deplete L-arginine from the tissue culture supernatants of murine renal cell carcinoma cell lines and determine their effect on cell proliferation. In adult mammals, the majority of endogenous L-arginine is synthesized from citrulline in the kidney and released to systemic circulation where it is catabolized by arginase I or arginase II [4, 11]. Therefore, the study of the L-arginine metabolic pathway in mRCC cell lines provide us with a good model to better understand the biology of renal carcinoma.
Western blot and RT-PCR analyses confirmed that arginase activity from mRCC cell lines was attributable solely to arginase II and not to arginase I. This is an important finding, since most studies have demonstrated that only arginase I produced by tumor cells, macrophages, smooth muscle and endothelial cells [26–29] is capable of depleting L-arginine which results in the induction of T-cell dysfunction [19, 30]. The role of arginase II on L-arginine metabolism in disease and cancer has been quite underestimated, especially taking into account its wide tissue distribution and its role in polyamine production. Previous studies have shown that the expression of either arginase I or arginase II plays a key role in polyamine synthesis and cell proliferation . Although the three cell lines used in this study were all derived from kidney tumors, they had very different arginase II activities. CL-2 and CL-19, both derived from renal tumors induced by streptozotocin, had low and high arginase II activities, respectively. The Renca cell line, derived from a spontaneous renal tumor had intermediate activity. These three lines provide us with an ideal model to study the biology of RCC with regard to L-arginine consumption, L-ornithine production, and cell proliferation. We demonstrate for the first time that arginase II produced by the high arginase RCC cell line CL-19 dramatically depletes L-arginine from the tissue culture supernatants at 48 hours with a concomitant increase in L-ornithine production.
In contrast, the cell lines CL-2 and Renca, both of which expressed low levels of arginase II compared to CL-19 did not deplete L-arginine significantly; nor did they increase the levels of L-ornithine sufficiently to promote growth. Instead, we observed that CL-2 and Renca cells utilize L-glutamine at higher rates than CL-19, suggesting that this could be a possible mechanism used by these cells to convert L-glutamine to glutamate, bypassing arginase for the production of L-ornithine as described previously in murine macrophages and human monocytes . It is likely that CL-2 and Renca cells do not need arginase to make L-ornithine because they utilize L-glutamine to produce the necessary amount of L-ornithine needed for their cell growth. This observation indicates that arginase II is important for CL-19 growth but not for CL-2 and Renca cells due to the positive effect of nor-NOHA in suppressing cell growth in CL-19. We used nor-NOHA in our experiments because it has been demonstrated that nor-NOHA is a potent and selective inhibitor of arginase  in contrast to NOHA which is a key intermediate product in the biosynthesis of nitric oxide by L-arginine. We were expecting to have a greater arginase inhibition by nor-NOHA in our cultures similar to those observed when NOHA was used to inhibit cell proliferation in cell lines from breast, colon, prostate and endothelial cells as previously reported [16, 17, 34, 35]. This may be due to the fact that these cell lines can use L-arginine to synthesize NOHA from arginase, then increasing its inhibitory effect. In contrast, it is also possible the growth of renal cell carcinoma cells is arginase II independent resulting in the low inhibitory effect of nor-NOHA.
At 48 hours in culture, CL-19 cells significantly depleted L-arginine from the culture supernatant; however, these cells continued growing at the same rate up to 120 hours in the absence of the amino acid (data not shown). L-arginine deprivation should promote the death of CL-19 cells, as reported previously to occur in other cancer cells lines [36, 37], indicating that these cells are more adept at circumventing L-arginine deficiency by increasing the recycling efficiency from L-ornithine to citrulline to convert L-arginine fast enough to sustain relatively normal tumor cell growth rate as previously shown . Since RCC cells have a strong dependence for L-arginine , our laboratory is currently studying whether or not these cells are utilizing L-glutamine or citrulline as the source for L-arginine synthesis.
L-arginine is a non-essential amino acid that plays a central role in several biological systems including the immune response. Paradoxically, L-arginine deprivation can cause tumor cell death as well as T-cell dysfunction. The loss of CD3ζ is the only arginase-triggered mechanism described so far that has proven to have direct relevance to T-cell function [40, 41]. It has been previously shown that Jurkat T-cells cultured in medium lacking L-arginine showed decreased expression of CD3ζ and decreased cell proliferation . Similar results were obtained when stimulated normal human T-cell lymphocytes were cultured in the absence of L-arginine . In the current experiments, we found that after 48 hours in culture, depletion of L-arginine by CL-19 arginase II activity caused the decreased expression of CD3ζ in co-cultured Jurkat T-cells. Therefore, L-arginine availability can regulate the expression of CD3ζ, an essential component in T-lymphocyte signal transduction and function. L-arginine levels in the serum of normal individuals ranges from 115 μM to 210 μM . Our data show that at 48 hours, the levels of L-arginine in the trans-well tissue culture supernatant was 100 μM, a concentration sufficient to induce a decrease in CD3ζ expression.
Most tumor cells have a great demand for amino acids to support rapid proliferation and L-arginine is the first amino acid depleted faster than other nutrients by normal cell metabolism. Therefore, L-arginine could be a reasonable target of deprivation strategy for the type of tumors with a low recycling efficiency. Taken collectively, these findings, demonstrate that the availability of L-arginine and L-ornithine could be the limiting factor to control cell proliferation. We believe that treating RCC cells downstream from the L-arginine metabolic pathway by blocking polyamine production will have a major impact in suppressing tumor growth. This is supported by the use of DL-α-difluoromethylornithine, which completely blocks the proliferation of these cell lines independent of the presence of L-arginine, L-ornithine and arginase in addition to the promising anti-tumor effect in human tumors [43–45].
Renal cell carcinoma is a malignancy with poor prognosis due to its strong resistance to conventional cancer treatments and frequent metastases. With the standard immunotherapeutic treatment of IL-2 and IFNα for RCC, only 10–20% of the patients respond . This lack of response may be caused by the markedly impaired T-cell function associated with a decreased expression of the CD3ζ receptor. Therefore, it is still desirable to find better approaches to treat RCC. Modulating the L-arginine metabolic pathway by breaking down this amino acid required for tumor cell growth could be a novel approach to control it. The study of the mechanisms by which arginase II activity and L-arginine depletion affect tumor growth will help better understand the biology of RCC and its interaction with the immune system. The results of these studies may provide future therapeutic benefits.
Arginase II produced by renal cell carcinoma cells can modulate L-arginine levels to regulate both cell growth and T cell function. Blocking arginase may lead to a decrease in RCC cell growth and aid in restoring immune function by blocking the formation of polyamines, thus providing a novel therapeutic advance.
The authors greatly thank Dr. Robert H. Wiltrout who kindly provided us with the cell lines, Drs. James Thompson and Ben L. Kelly for the critical review of the manuscript, Dr. Heidi Davis for helping in editing of the manuscript and Claudia Hernandez for her technical assistance.
- Brittenden J, Heys SD, Ross J, Park KG, Eremin O: Nutritional pharmacology: effects of L-arginine on host defences, response to trauma and tumour growth. Clin Sci (Lond). 1994, 86: 123-132.View ArticleGoogle Scholar
- Albina JE, Caldwell MD, Henry WL, Mills CD: Regulation of macrophage functions by L-arginine. J Exp Med. 1989, 169: 1021-1029. 10.1084/jem.169.3.1021.View ArticlePubMedGoogle Scholar
- Ochoa JB, Strange J, Kearney P, Gellin G, Endean E, Fitzpatrick E: Effects of L-arginine on the proliferation of T lymphocyte subpopulations. JPEN J Parenter Enteral Nutr. 2001, 25: 23-29. 10.1177/014860710102500123.View ArticlePubMedGoogle Scholar
- Wu G, Morris SM: Arginine metabolism: nitric oxide and beyond. Biochem J. 1998, 336 (Pt 1): 1-17.PubMed CentralView ArticlePubMedGoogle Scholar
- Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol. 1982, 243: C212-C221.PubMedGoogle Scholar
- Miyanaka K, Gotoh T, Nagasaki A, Takeya M, Ozaki M, Iwase K, Takiguchi M, Iyama KI, Tomota K, Mori M: Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem J. 1998, 30: 741-751. 10.1023/A:1003468726969.View ArticlePubMedGoogle Scholar
- Bernard A, Kasten M, Meier C, Manning E, Freeman S, Adams W, Chang P, Boulanger B, Kearney P: Red blood cell arginase suppresses Jurkat (T cell) proliferation by depleting arginine. Surgery. 2008, 143: 286-291. 10.1016/j.surg.2007.07.037.View ArticlePubMedGoogle Scholar
- Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, Luckner C, Doschko G, Soler G, Eichmann K, Muller FM, Ho AD, Goerner M, Modolell M: Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood. 2005, 105: 2549-2556. 10.1182/blood-2004-07-2521.View ArticlePubMedGoogle Scholar
- Gotoh T, Araki M, Mori M: Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun. 1997, 233: 487-491. 10.1006/bbrc.1997.6473.View ArticlePubMedGoogle Scholar
- Braissant O, Gotoh T, Loup M, Mori M, Bachmann C: L-arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study. Brain Res Mol Brain Res. 1999, 70: 231-241. 10.1016/S0169-328X(99)00151-5.View ArticlePubMedGoogle Scholar
- Jenkinson CP, Grody WW, Cederbaum SD: Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol. 1996, 114: 107-132. 10.1016/0305-0491(95)02138-8.View ArticlePubMedGoogle Scholar
- Bernard AC, Mistry SK, Morris SM, O'Brien WE, Tsuei BJ, Maley ME, Shirley LA, Kearney PA, Boulanger BR, Ochoa JB: Alterations in arginine metabolic enzymes in trauma. Shock. 2001, 15: 215-219.View ArticlePubMedGoogle Scholar
- Jacob TD, Ochoa JB, Udekwu AO, Wilkinson J, Murray T, Billiar TR, Simmons RL, Marion DW, Peitzman AB: Nitric oxide production is inhibited in trauma patients. J Trauma. 1993, 35: 590-596.View ArticlePubMedGoogle Scholar
- Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmas A, O'Neill A, Mier J, Ochoa AC: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65: 3044-3048.PubMedGoogle Scholar
- Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD: Cloning and characterization of the human type II arginase gene. Genomics. 1996, 38: 118-123. 10.1006/geno.1996.0606.View ArticlePubMedGoogle Scholar
- Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G: Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 2000, 60: 3305-3312.PubMedGoogle Scholar
- Buga GM, Wei LH, Bauer PM, Fukuto JM, Ignarro LJ: NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am J Physiol. 1998, 275: R1256-R1264.PubMedGoogle Scholar
- Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW: Expression of arginase II in prostate cancer. Int J Oncol. 2008, 32: 357-365.PubMedGoogle Scholar
- Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003, 171: 1232-1239.View ArticlePubMedGoogle Scholar
- Deignan JL, Livesay JC, Yoo PK, Goodman SI, O'Brien WE, Iyer RK, Cederbaum SD, Grody WW: Ornithine deficiency in the arginase double knockout mouse. Mol Genet Metab. 2006, 89: 87-96. 10.1016/j.ymgme.2006.04.007.View ArticlePubMedGoogle Scholar
- Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, O'Brien WE, YU H, Grody WW, Cederbaum SD: Mouse model for human arginase deficiency. Mol Cell Biol. 2002, 22: 4491-4498. 10.1128/MCB.22.13.4491-4498.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton HM, Wiltrout RH: Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype. Cancer Res. 2001, 61: 6255-6263.PubMedGoogle Scholar
- Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'Shea JJ, Powers GC, Urba WJ, Ochoa AC: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995, 1: 1327-1335.PubMedGoogle Scholar
- Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF, Ochoa AC: Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis. 2006, 194: 1385-1393. 10.1086/508200.View ArticlePubMedGoogle Scholar
- Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, Ochoa JB, Park HJ, Zabaleta J, Ochoa AC: L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004, 232: 21-31. 10.1016/j.cellimm.2005.01.004.View ArticlePubMedGoogle Scholar
- Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK: Arginases I and II: do their functions overlap?. Mol Genet Metab. 2004, 81 (Suppl 1): S38-S44. 10.1016/j.ymgme.2003.10.012.View ArticlePubMedGoogle Scholar
- Kepka-Lenhart D, Mistry SK, Wu G, Morris SM: Arginase I: a limiting factor for nitric oxide and polyamine synthesis by activated macrophages?. Am J Physiol Regul Integr Comp Physiol. 2000, 279: R2237-R2242.PubMedGoogle Scholar
- Wei LH, Wu G, Morris SM, Ignarro LJ: Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci (USA). 2001, 98: 9260-9264. 10.1073/pnas.161294898.View ArticleGoogle Scholar
- Li H, Meininger CJ, Kelly KA, Hawker JR, Morris SM, Wu G: Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol Regul Integr Comp Physiol. 2002, 282: R64-R69.PubMedGoogle Scholar
- Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, Kropf P, Mueller I, Kolb A, Modolell M, Ho AD: Suppression of T-cell functions by human granulocyte arginase. Blood. 2006, 108: 1627-1634. 10.1182/blood-2006-11-010389.View ArticlePubMedGoogle Scholar
- Li H, Meininger CJ, Hawker JR, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM, Wu G: Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001, 280: E75-E82.PubMedGoogle Scholar
- Murphy C, Newsholme P: Importance of glutamine metabolism in murine macrophages and human monocytes to L-arginine biosynthesis and rates of nitrite or urea production. Clin Sci (Lond). 1998, 95: 397-407.View ArticleGoogle Scholar
- Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Bouche JL: Effects of the new arginase inhibitor N (omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide. 1999, 3: 427-438. 10.1006/niox.1999.0255.View ArticlePubMedGoogle Scholar
- Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, Viola A: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005, 201: 1257-1268. 10.1084/jem.20042028.PubMed CentralView ArticlePubMedGoogle Scholar
- Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SD, Ignarro LJ: Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol. 1996, 271: H1988-H1998.PubMedGoogle Scholar
- Scott L, Lamb J, Smith S, Wheatley DN: Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer. 2000, 83: 800-810. 10.1054/bjoc.2000.1353.PubMed CentralView ArticlePubMedGoogle Scholar
- Philip R, Campbell E, Wheatley DN: Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. Br J Cancer. 2003, 88: 613-623. 10.1038/sj.bjc.6600681.PubMed CentralView ArticlePubMedGoogle Scholar
- Wheatley DN, Campbell E: Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilization of citrulline by malignant cells. Br J Cancer. 2003, 89: 573-576. 10.1038/sj.bjc.6601134.PubMed CentralView ArticlePubMedGoogle Scholar
- Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH: Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deaminase. Int J Cancer. 2007, 120: 897-905. 10.1002/ijc.22322.View ArticlePubMedGoogle Scholar
- Bronte V, Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005, 5: 641-654. 10.1038/nri1668.View ArticlePubMedGoogle Scholar
- Baniyash M: TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004, 4: 675-687. 10.1038/nri1434.View ArticlePubMedGoogle Scholar
- Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park HJ, Lan MS, Zea AH, Ochoa AC: L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res. 2001, 7: 958s-965s.PubMedGoogle Scholar
- Selamnia M, Mayeur C, Robert V, Blachier F: α-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochemical Pharmacology. 1998, 55: 1241-1245. 10.1016/S0006-2952(97)00572-8.View ArticlePubMedGoogle Scholar
- Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H: Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice. Cancer Res. 2000, 60: 5125-5133.PubMedGoogle Scholar
- Simoneau AR, Gerner EW, Nagle R, Argyrios Ziogas A, Fujikawa-Brooks S, Hagit Yerushalmi H, Ahlering TE, Lieberman R, Christine E, McLaren CE, Anton-Culver H, Frank L, Meyskens FL: The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiology Markers. 2008, 17: 292-299. 10.1158/1055-9965.EPI-07-0658.View ArticleGoogle Scholar
- Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ: Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol. 2003, 20: 271-281. 10.1385/MO:20:3:271.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.